Lung and skin multiple primary cancer: clinical case description


DOI: https://dx.doi.org/10.18565/therapy.2021.3.100-105

Semenkin A.A., Vorotilina L.V., Sapronenko V.S., Zhivilova L.A., Drokina O.V.

1) Omsk State Medical University of the Ministry of Healthcare of Russia; 2) Clinical Oncological Dispensary, Omsk
Abstract. The clinical case is presented of multiple primary cancers of the lung and the skin in the 82-years old patient. The combination of a lung and a skin cancer is not the rare one among multiple primary tumors as in the cases when the first tumor is formed in the lung and vice versa. The special feature of this case is the fact of the late diagnostics of the visible skin tumor and as the consequence – the lung cancer. On the one hand, this case demonstrates the need for the targeted exclusion of tumors of other locations after diagnosis of the cancer. On the other hand, it shows the importance of non-formal approach to cancer prevention and preventive medical examinations of practitioners of any specialization.
Keywords: multiple primary cancer, lung adenocarcinoma, skin cancer, late diagnostics, cancer prevention
Read entire article

Literature


  1. Саидов Г.Н., Абдукаримов У.Г., Махмудова Г.Ф. Эпидемиологические показатели первично-множественных опухолей (обзор литературы). Биология и интегративная медицина. 2019; 11: 31–42. [Saidov G.N., Abdukarimov U.G., Mahmudova G.F. Epidemiological indicators of primary-multiple tumors (review of literature). Biologiya i integrativnaya meditsina = Biology and integrative medicine. 2019; 11: 31–42 (In Russ.)].

  2. Артемова Н.А. Первично-множественные злокачественные опухоли, одной из которых является рак легкого, в Республике Беларусь. Вопросы организации и информатизации здравоохранения. 2009; 3: 22–34. [Artemova N.A. Primary multiple malignant tumors, one of which is lung cancer, in the Republic of Belarus. Voprosy organizatsii i informatizatsii zdravookhraneniya = Organization and informatization of healthcare. 2009; 3: 22–34 (In Russ.)].

  3. Понкратова Д.А., Цыганова И.В., Вихрова А.С., Лушникова А.А. Характеристика пациентов с меланомой кожи и первично-множественным злокачественными опухолями: клинические наблюдения. Российский биотерапевтический журнал. 2017; 3: 43–51. [Ponkratova D.A., Cyganova I.V., Vihrova A.S., Lushnikova A.A. Characteristics of the patients with cutaneous melanoma and multiple primary malignant tumors: Clinical observations. Rossiyskiy bioterapevticheskiy zhurnal = Russian biotherapeutic journal. 2017; 3: 43–51 (In Russ.)]. doi: https://dx.doi.org/10.17650/1726-9784-2017-16-3-43-51.

  4. Степанова Ю.А., Калинин Д.В., Вишневский В.А. Первично-множественные опухоли. Медицинская визуализация. 2015; 6: 93–102. [Stepanova Yu.A., Kalinin D.V., Vishnevskij V.A. Multiple primary tumors. Meditsinskaya vizualizatsiya = Medical imaging. 2015; 6: 93–102 (In Russ.)].

  5. Лактионов К.К., Артамонова Е.В., Бредер В.В. с соавт. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Злокачественные опухоли: практические рекомендации RUSSCO. 2020; 3s2; 39–58. [Laktionov K.K., Artamonova E.V., Breder V.V. et al. Practical guidelines for drug treatment of non-small cell lung cancer. Zlokachestvennye opuholi: Prakticheskie rekomendatsii RUSSCO = Malignant tumors: practical recommendations of RUSSCO. 2020; 3s2: 39–58 (In Russ.)]. doi: https://dx.doi.org/10.18027/2224-5057-2020-10-3s2-02.

  6. Строяковский Д.Л., Абрамов М.Е., Демидов Л.В. с соавт. Практические рекомендации по лекарственному лечению меланомы кожи. Злокачественные опухоли: Практические рекомендации RUSSCO. 2020; 3s2: 266–281. [Stroyakovskij D.L., Abramov M.E., Demidov L.V., Zhukova N.V. et al. Practical guidelines for drug treatment of skin melanoma. Zlokachestvennye opuholi: Prakticheskie rekomendatsii RUSSCO = Malignant tumors: practical recommendations of RUSSCO. 2020; 3s2: 266–281 (In Russ.)]. doi: https://dx.doi.org/10.18027/2224-5057-2020-10-3s2-16.

  7. American Cancer Society. Lung Cancer Survival Rates. URL: https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html (date of access – 02.03.2021).

  8. Тюляндин С.А. Таргетная терапия: двадцать лет успехов и поражений. Практическая онкология. 2019; 4: 274–288. [Tyulyandin S.A. Targeted therapy: Twenty years of success and failures. Prakticheskaya onkologiya = Practical oncology. 2019; 4: 274–288 (In Russ.)]. doi: https://dx.doi.org/10.31917/2004274.

  9. Mok T., Yang J.-J., Lam K.-C. Treating patients with EGFR-sensitizing mutations: first line or second line – is there a difference? J Clin Oncol. 2013; 31(8); 1081–88. doi: 10.1200/JCO.2012.43.0652.

  10. Peters S., Camidge D.R., Shaw A.T. et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017; 377(9): 829–38. doi: 10.1056/NEJMoa1704795.

  11. Shaw A.T., Ou S.H., Bang Y.J. et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 371(21): 1963–71. doi: 10.1056/NEJMoa1406766.

  12. Лактионов К.К., Реутова Е.В., Нелюбина Л.А. с соавт. Новые возможности в лечении EGFR-позитивных больных немелкоклеточным раком легкого после прогрессирования на ингибиторах тирозинкиназ EGFR I–II поколений. Клиническая онкология. 2018; 2: 50–54. [Laktionov K.K., Reutova E.V., Nelyubina L.A. et al. New possibilities in the treatment of EGFR mutation-positive non-small-cell lung cancer patients after the progression on a 1st and 2nd generation egfr tyrosine kinase inhibitors. Klinicheskaya onkologiya = Clinical oncology. 2018; 2: 50–54 (In Russ.)]. doi: https://dx.doi.org/10.26442/1815-1434_2018.2.50-54.

  13. Лактионов К.К., Реутова Е.В., Кормош Н.Г. с соавт. Лорлатиниб у ALK-позитивных больных НМРЛ после прогрессирования на кризотинибе. Результаты предварительного анализа. Вопросы онкологии. 2019; 3; 386–392. [Laktionov K.K., Reutova E.V., Kormosh N.G. et al. Lorlatinib in crisotinib-resistant ALK+ NSCLC patients. Our result. Voprosy onkologii = Oncology issues. 2019; 3: 386–392 (In Russ.)].


About the Autors

Alexander A. Semenkin, MD, professor, professor of the Department of internal medicine and family medicine (postgraduate course), Omsk State Medical University of the Ministry of Healthcare of Russia. Address: 644033, Omsk, 127/1 Krasny put` Str. Tel.: +7 (950) 958-53-01. E-mail: asemyonkin@mail.ru. ORCID: 0000-0002-3786-9995
Lyudmila V. Vorotilina, oncologist of Clinical Oncological Dispensary. Address: 644013, Omsk, 9/1 Zavertyaev Str.
Tel.: +7 (913) 676-61-21. E-mail: vorolu@rambler.ru
Vladimir S. Sapronenko, 5th year student of medical Faculty, Omsk State Medical University of the Ministry of Healthcare of Russia. Address: 644099, Omsk, 12 Lenin Str. Tel.: +7 (913) 620-53-30. E-mail: vssapronenko@mail.ru. ORCID: 0000-0002-4462-569X
Lilia A. Zhivilova, PhD, associate professor, associate professor of the Department of propaedeutics of internal diseases, Omsk State Medical University of the Ministry of Healthcare of Russia. Address: 644112, Omsk, 7 Pereleta Str.
Tel.: +7 (904) 582-25-99. E-mail: liliya.zhivilova@yandex.ru
Olga V. Drokina, PhD, PhD, associate professor, associate professor of the Department of propaedeutics of internal diseases, Omsk State Medical University of the Ministry of Healthcare of Russia. Address: 644112, Omsk, 7 Pereleta Str. Tel.:: +7 (913) 975-67-15. E-mail: amans@bk.ru

Back to Content

Бионика Медиа